Psychiatric and Substance Use Disorders among Methadone Maintenance Patients with Chronic Hepatitis C Infection: Effects on Eligibility for Hepatitis C Treatment
Identifieur interne : 000824 ( 2020/Analysis ); précédent : 000823; suivant : 000825Psychiatric and Substance Use Disorders among Methadone Maintenance Patients with Chronic Hepatitis C Infection: Effects on Eligibility for Hepatitis C Treatment
Auteurs : Steven L. Batki [États-Unis] ; Kelly M. Canfield [États-Unis] ; Robert Ploutz-Snyder [États-Unis]Source :
- The American Journal on Addictions [ 1055-0496 ] ; 2011-07.
English descriptors
- Teeft :
- Addiction, Addiction psychiatrist, American association, Antisocial personality disorder, Anxiety disorder, Anxiety disorders, Beck, Beck anxiety inventory, Beck depression inventory, Chronic hepatitis, Clin, Clinic, Clinical experience, Cocaine, Cocaine dependence, Current suds, Demographic characteristics, Depression severity, Depressive disorder, Diagnostic data, Disease severity, Disorder, Drug abuse, Drug alcohol, Eligibility, Entry criteria, Evaluation process, Fatigue severity, Gastroenterol hepatol, Hcvtreatment eligibility, Hepatitis, High prevalence, Hivhcv coinfection clinic, Injection drug, Injection drug users, Interferon, Liver diseases, Logistic regression, Medical center, Medical insurance, Medical treatment, Medical university, Medication, Methadone, Methadone maintenance patients, Methadone maintenance treatment, Mood disorder, Mood disorders, Opioid, Opioid abusers, Panic disorder, Participant, Pegylated interferon, Predictive accuracy, Psychiatric, Psychiatric barriers, Psychiatric comorbidity, Psychiatric diagnoses, Psychiatric diagnosis, Psychiatric disorder block, Psychiatric disorders, Psychiatric illness, Psychiatric medication, Psychiatric medications, Psychological corporation, Psychotic, Psychotic disorder, Public health, Public health hospital, Research psychiatrist, Ribavirin, Scid substance, Severity, Social phobia, Study design, Study entry, Subst abuse, Symptom severity, Treatment eligibility, Treatment initiation, Urine drug testing, Virus infection.
Abstract
We set out to describe the prevalence and severity of psychiatric and substance use disorders (SUDs) in methadone maintenance treatment (MMT) patients with chronic hepatitis C virus (HCV) infection and to measure the impact on HCV‐treatment eligibility. Psychiatric disorders, SUDs, and HCV‐treatment eligibility were assessed in 111 MMT patients prior to a controlled trial of HCV treatment. Lifetime and current diagnosis rates, respectively, were: any non‐SUD Axis I disorder: 82% and 57%, any mood disorder: 67% and 35%, any anxiety disorder: 63% and 22%, any psychotic disorder: 11% and 9%. Antisocial personality disorder was present in 40%. A total of 56% met criteria for current SUDs. A total of 66% received psychiatric medications prior to HCV treatment; over half were receiving antidepressants. Despite psychiatric and substance use comorbidity, only 15% of patients were ineligible for HCV treatment: 10% due to failure to complete the evaluation, and 5% due to psychiatric severity. Substance use did not lead to ineligibility in any participant. Multiple logistic regression showed the Beck Depression Inventory contributed significantly to predicting HCV treatment eligibility. Most MMT patients were eligible for HCV treatment despite current SUD and non‐SUD diagnoses. Depression severity may be a more significant predictor of HCV treatment eligibility than is substance use. (Am J Addict 2011;00:1–7)
Url:
DOI: 10.1111/j.1521-0391.2011.00139.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000543
- to stream Istex, to step Curation: 000543
- to stream Istex, to step Checkpoint: 000571
- to stream Main, to step Merge: 001606
- to stream Main, to step Curation: 001604
- to stream Main, to step Exploration: 001604
- to stream 2020, to step Extraction: 000824
Links to Exploration step
ISTEX:032020E18F81AE2DB0EDB0F93C04E3DDE50E7C5ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Psychiatric and Substance Use Disorders among Methadone Maintenance Patients with Chronic Hepatitis C Infection: Effects on Eligibility for Hepatitis C Treatment</title><author><name sortKey="Batki, Steven L" sort="Batki, Steven L" uniqKey="Batki S" first="Steven L." last="Batki">Steven L. Batki</name></author><author><name sortKey="Canfield, Kelly M" sort="Canfield, Kelly M" uniqKey="Canfield K" first="Kelly M." last="Canfield">Kelly M. Canfield</name></author><author><name sortKey="Ploutz Nyder, Robert" sort="Ploutz Nyder, Robert" uniqKey="Ploutz Nyder R" first="Robert" last="Ploutz-Snyder">Robert Ploutz-Snyder</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:032020E18F81AE2DB0EDB0F93C04E3DDE50E7C5A</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1521-0391.2011.00139.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-8XRQWK6Z-L/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000543</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000543</idno><idno type="wicri:Area/Istex/Curation">000543</idno><idno type="wicri:Area/Istex/Checkpoint">000571</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000571</idno><idno type="wicri:doubleKey">1055-0496:2011:Batki S:psychiatric:and:substance</idno><idno type="wicri:Area/Main/Merge">001606</idno><idno type="wicri:Area/Main/Curation">001604</idno><idno type="wicri:Area/Main/Exploration">001604</idno><idno type="wicri:Area/2020/Extraction">000824</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Psychiatric and Substance Use Disorders among Methadone Maintenance Patients with Chronic Hepatitis C Infection: Effects on Eligibility for Hepatitis C Treatment</title><author><name sortKey="Batki, Steven L" sort="Batki, Steven L" uniqKey="Batki S" first="Steven L." last="Batki">Steven L. Batki</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Psychiatry, University of California, San Francisco and San Francisco VA Medical Center, San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Canfield, Kelly M" sort="Canfield, Kelly M" uniqKey="Canfield K" first="Kelly M." last="Canfield">Kelly M. Canfield</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Psychiatry, SUNY Upstate Medical University, Syracuse</wicri:cityArea></affiliation></author><author><name sortKey="Ploutz Nyder, Robert" sort="Ploutz Nyder, Robert" uniqKey="Ploutz Nyder R" first="Robert" last="Ploutz-Snyder">Robert Ploutz-Snyder</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Universities Space Research Associations, Houston</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">The American Journal on Addictions</title><title level="j" type="alt">AMERICAN JOURNAL ON ADDICTIONS</title><idno type="ISSN">1055-0496</idno><idno type="eISSN">1521-0391</idno><imprint><biblScope unit="vol">20</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="312">312</biblScope><biblScope unit="page" to="318">318</biblScope><biblScope unit="page-count">7</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-07">2011-07</date></imprint><idno type="ISSN">1055-0496</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1055-0496</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Addiction</term><term>Addiction psychiatrist</term><term>American association</term><term>Antisocial personality disorder</term><term>Anxiety disorder</term><term>Anxiety disorders</term><term>Beck</term><term>Beck anxiety inventory</term><term>Beck depression inventory</term><term>Chronic hepatitis</term><term>Clin</term><term>Clinic</term><term>Clinical experience</term><term>Cocaine</term><term>Cocaine dependence</term><term>Current suds</term><term>Demographic characteristics</term><term>Depression severity</term><term>Depressive disorder</term><term>Diagnostic data</term><term>Disease severity</term><term>Disorder</term><term>Drug abuse</term><term>Drug alcohol</term><term>Eligibility</term><term>Entry criteria</term><term>Evaluation process</term><term>Fatigue severity</term><term>Gastroenterol hepatol</term><term>Hcvtreatment eligibility</term><term>Hepatitis</term><term>High prevalence</term><term>Hivhcv coinfection clinic</term><term>Injection drug</term><term>Injection drug users</term><term>Interferon</term><term>Liver diseases</term><term>Logistic regression</term><term>Medical center</term><term>Medical insurance</term><term>Medical treatment</term><term>Medical university</term><term>Medication</term><term>Methadone</term><term>Methadone maintenance patients</term><term>Methadone maintenance treatment</term><term>Mood disorder</term><term>Mood disorders</term><term>Opioid</term><term>Opioid abusers</term><term>Panic disorder</term><term>Participant</term><term>Pegylated interferon</term><term>Predictive accuracy</term><term>Psychiatric</term><term>Psychiatric barriers</term><term>Psychiatric comorbidity</term><term>Psychiatric diagnoses</term><term>Psychiatric diagnosis</term><term>Psychiatric disorder block</term><term>Psychiatric disorders</term><term>Psychiatric illness</term><term>Psychiatric medication</term><term>Psychiatric medications</term><term>Psychological corporation</term><term>Psychotic</term><term>Psychotic disorder</term><term>Public health</term><term>Public health hospital</term><term>Research psychiatrist</term><term>Ribavirin</term><term>Scid substance</term><term>Severity</term><term>Social phobia</term><term>Study design</term><term>Study entry</term><term>Subst abuse</term><term>Symptom severity</term><term>Treatment eligibility</term><term>Treatment initiation</term><term>Urine drug testing</term><term>Virus infection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We set out to describe the prevalence and severity of psychiatric and substance use disorders (SUDs) in methadone maintenance treatment (MMT) patients with chronic hepatitis C virus (HCV) infection and to measure the impact on HCV‐treatment eligibility. Psychiatric disorders, SUDs, and HCV‐treatment eligibility were assessed in 111 MMT patients prior to a controlled trial of HCV treatment. Lifetime and current diagnosis rates, respectively, were: any non‐SUD Axis I disorder: 82% and 57%, any mood disorder: 67% and 35%, any anxiety disorder: 63% and 22%, any psychotic disorder: 11% and 9%. Antisocial personality disorder was present in 40%. A total of 56% met criteria for current SUDs. A total of 66% received psychiatric medications prior to HCV treatment; over half were receiving antidepressants. Despite psychiatric and substance use comorbidity, only 15% of patients were ineligible for HCV treatment: 10% due to failure to complete the evaluation, and 5% due to psychiatric severity. Substance use did not lead to ineligibility in any participant. Multiple logistic regression showed the Beck Depression Inventory contributed significantly to predicting HCV treatment eligibility. Most MMT patients were eligible for HCV treatment despite current SUD and non‐SUD diagnoses. Depression severity may be a more significant predictor of HCV treatment eligibility than is substance use. (Am J Addict 2011;00:1–7)</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Texas</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Batki, Steven L" sort="Batki, Steven L" uniqKey="Batki S" first="Steven L." last="Batki">Steven L. Batki</name></region><name sortKey="Canfield, Kelly M" sort="Canfield, Kelly M" uniqKey="Canfield K" first="Kelly M." last="Canfield">Kelly M. Canfield</name><name sortKey="Ploutz Nyder, Robert" sort="Ploutz Nyder, Robert" uniqKey="Ploutz Nyder R" first="Robert" last="Ploutz-Snyder">Robert Ploutz-Snyder</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000824 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000824 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= 2020
|étape= Analysis
|type= RBID
|clé= ISTEX:032020E18F81AE2DB0EDB0F93C04E3DDE50E7C5A
|texte= Psychiatric and Substance Use Disorders among Methadone Maintenance Patients with Chronic Hepatitis C Infection: Effects on Eligibility for Hepatitis C Treatment
}}
| This area was generated with Dilib version V0.6.33. |  |